立体定向放射外科作为脑动静脉畸形的预期治愈性治疗:前瞻性实用试验注册研究结果
TOBAS研究的前瞻性SRS注册队列纳入94例脑动静脉畸形患者,多数为破裂、小型、位于功能区。平均随访51个月,改良Rankin量表>2分者7%,严重不良事件17%,3年影像随访证实闭塞率54%-65%。SRS联合或不联合栓塞相对安全但疗效中等。
要点
- SRS治疗脑AVM的3年闭塞率约为54%-65%,疗效中等。
- 严重不良事件发生率17%,AVM破裂5%,症状性放射性改变7%。
- 多数患者为破裂、小型(0-3 cm)、位于功能区的AVM。
核心结论
- SRS联合或不联合栓塞治疗脑AVM相对安全,但3年闭塞率为54%-65%,疗效中等。
研究设计与样本
- TOBAS实用研究的前瞻性SRS注册队列,2014年6月至2021年5月共招募1010例,105例(10.4%)进入SRS注册,排除后94例纳入分析。
主要发现
- 平均随访51个月,主要结局mRS>2分 occurred in 7/94(7%,95%CI 4%-15%)。
- 严重不良事件16/94(17%,95%CI 11%-26%),包括AVM破裂5/94(5%,95%CI 2%-12%)。
- 症状性放射性改变6/87(7%,95%CI 3%-14%)。
- 3年影像随访79/94(84%)证实AVM闭塞51/79(65%,95%CI 54%-74%)或全部患者中54%(95%CI 44%-64%)。
关键数值与推荐
- SRS中位剂量22 Gy(四分位距20-24)。
- 94例中64例(68%)为破裂AVM,84例(89%)为小型AVM(0-3 cm),57例(61%)位于功能区。
- 术前栓塞19例(20%),其中4例治愈,3例出现血管内并发症,最终87/94(93%)接受SRS。
临床怎么用
- 对于破裂、小型、位于功能区的AVM,SRS可作为预期治愈性治疗选择之一,但需告知3年闭塞率约54%-65%。
- 术前栓塞可能治愈部分患者,但需注意血管内并发症风险。
局限性
- 注册队列非随机对照,样本量较小(94例),3年影像随访仅84%可评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Treatment Of Brain Arteriovenous malformations Study is a pragmatic study comprising 2 randomized trials and prospective registries of patients with brain arteriovenous malformations (AVMs). We report the results of the stereotactic radiosurgery (SRS) registry. METHODS: TOBAS uses an algorithm integrating clinical judgment and randomization. When SRS was selected as the preferred curative modality and randomized allocation of SRS versus observation was judged unreasonable, patients were included in the SRS registry (with/without pre-SRS embolization). The primary outcome was modified Rankin Scale > 2 at last follow-up. Secondary outcomes included serious adverse events, AVM rupture, radiation-induced changes, and magnetic resonance angiographic results at 3 years. Analyses were intent-to-treat. RESULTS: From June 2014 to May 2021, 1010 patients were recruited; 105 (10.4%) were offered participation in the SRS registry. After exclusions, 94 patients were analyzed; most had ruptured (n = 64/94 [68%]), small AVMs (0-3 cm) (84 [89%]), within eloquent brain (57 [61%]). Pre-SRS embolization was performed in 19 (20%); 4 were cured and 3 had endovascular complications, leaving 87/94 (93%) patients who received SRS. The median SRS dose was 22 Gy (interquartile range: 20-24). During a mean follow-up of 51 months, the primary outcome (modified Rankin Scale > 2) occurred in 7/94 (7%; 95% confidence interval [CI]: 4%-15%), with serious adverse events in 16/94 (17%; 95% CI: 11%-26%), including AVM rupture in 5/94 (5%; 95% CI: 2%-12%), and symptomatic radiation-induced changes in 6/87 (7%; 95% CI: 3%-14%). Three-year imaging follow-up, available in 79/94 (84%) confirmed AVM occlusion in 51/79 (65%; 95% CI: 54%-74%) or 54% (95% CI: 44%-64%) of all patients. CONCLUSIONS: In this prospective registry, radiosurgery with or without embolization was relatively safe, but of moderate efficacy, with 3-year AVM occlusion in 54%-65% patients.
引用
- Alhazmi H, Darsaut TE, Gentric JC, et al. Stereotactic Radiosurgery for Brain Arteriovenous Malformations as Expected Curative Treatment: Outcomes of Patients Included in the Prospective Registry of a Pragmatic Trial. World Neurosurg. 2026. PMID: 42140314. doi:10.1016/j.wneu.2026.125056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。